New drug TAK-781 enters early safety testing for liver disease PSC
NCT ID NCT07229911
First seen Nov 17, 2025 · Last updated Apr 28, 2026 · Updated 22 times
Summary
This early-phase study tests whether the experimental drug TAK-781 is safe and tolerable. First, healthy volunteers receive either the drug or a placebo. Then, people with primary sclerosing cholangitis (PSC) receive the drug to see how their bodies handle it. The study does not aim to cure PSC, but to gather safety data for future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ICON
RECRUITINGSalt Lake City, Utah, 84124, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.